A cost comparison of treatments of moderate to severe psoriasis

Drug Benefit Trends

Volumn 17, Issue 5, 2005, Pages 200-214

  Hankin, Cheryl S ^a   Feldman, Steven R ^b   Szczotka, Andy ^c   Stinger, Randolph C ^c   Fish, Leslie ^c   Hankin, David L ^a  

^a BioMedEcon LLC   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Humana ^*

Author keywords

Cost effectiveness; Psoriasis; Psoriasis Area and Severity Index

Indexed keywords

ALEFACEPT; ATORVASTATIN; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; METHOXSALEN;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER TOXICITY; LYMPHOMA; MANAGED CARE; OUTCOMES RESEARCH; PHOTOTHERAPY; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

EID: 23944523103     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496.
3. Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003;49(suppl):S39-S43.
4. National Psoriasis Foundation. When are patients candidates for phototherapy or systemic treatments (including biologies)? Available at: www.psoriasis.org/medical/advocacy/2003_systemicsdiagram.php. Accessed April 14, 2005.
5. Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
6. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158-165.
7. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant end-point in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-866.
8. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-430.
9. Justice AC, Cho MK, Winker MA, et al. Does masking author identity improve peer review quality? A randomized controlled trial. JAMA. 1998;28:240-242.
10. Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol. 2003;139:795-798.
11. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol. 2001;144:1154-1160.
12. Red Book. 2004 ed. Montvale, NJ: Thomson Micromedex; 2004.
13. RBRVS EZ-Fees [computer program]. Version 7.0.2. Milwaukee: Yale Wasserman DMD Medical Publishers Ltd; 2004.
14. Neoral [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2004.
15. Raptiva [package insert]. South San Francisco, Calif: Genentech, Inc; 2004.
16. Remicade [package insert]. Malvern, Pa: Centocor, Inc; 2003.
17. Amevive [package insert]. Cambridge, Mass: Biogen, Inc; 2003.
18. Koo J, Bandow G, Feldman SR. The art and practice of UVB phototherapy for the treatment of psoriasis. In: Weinstein GD, Gottleib AB, eds. Therapy of Moderate-to-Severe Psoriasis. 2nd ed, revised and expanded. New York: Marcel Dekker; 2003:53-90.
19. Morison WL. Systemic and topical PUVA therapy. In: Weinstein GD, Gottleib AB, eds. Therapy of Moderate-to-Severe Psoriasis. 2nd ed, revised and expanded. New York: Marcel Dekker; 2003:91-114.
20. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41(3 pt 2): S22-S24.
21. Enbrel [package insert]. Thousand Oaks, Calif: Immunex Corporation; 2004.
22. Current Procedural Terminology: CPT 2004. Professional ed. Chicago: American Medical Association; 2004.
23. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
24. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073-3080.
25. Pasker-de Jong PC, Wielink G, van der Valk PG, van der Wilt GJ. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol 1999;135:834-840.
26. Housman TS, Feldman SR, Williford PM. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425-429.
27. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 pt 1):774-778.
28. Soriatane [package insert]. Palo Alto, Calif: Connetics Inc; 2004.
29. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments of plaque-type psoriasis. Drug Saf. 2002;25:913-927.
30. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41(pt 2):S7-S12.
31. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-475.
32. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-485.
33. Malatjalian D, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scoria, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;10:369-375.
34. Weinstein G, Roenigk H, Maibach H, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol. 1973;108:36-42.
35. Whiting-O'Keefe QE, Fye KH, Sach KD, Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-716.
36. Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45:544-553.
37. Levine N. Role of retinoids in skin cancer treatment and prevention. J Am Acad Dermatol. 1998;39(pt 3):S62-S66.
38. Smit JV, de Sevaux RG, Blokx WA, et al. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: histologic and immunohistochemical effects. J Am Acad Dermatol. 2004;50:189-196.
39. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003;49:644-650.
40. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003;49(suppl):S118-S124.
41. Ramsay CA, Schwartz BE, Lowson D, et al, for the Canadian Calcipotriol and UVB Study Group. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. Dermatology. 2000;200:17-24.
42. Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol 2003;149:146-150.
43. Walters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999;40:893-900.
44. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing Research. Cambridge, Mass: Harvard University Press; 1984.
45. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol. 2003;148:1153-1160.
46. Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis: a pilot study. Arch Dermatol 1998;134:1602-1608.
47. McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol. 1996;34:534-538.
48. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41:51-59.
49. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclo-sporine and methotrexate. J Am Acad Dermatol. 2002;46:242-250.
50. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000; the EDEN Survey. J Invest Dermatol. 2003;120:739-741.
51. Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1-125.
52. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol. 1997;137:943-949.
53. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(pt 1):401-407.
54. Feldman SR, Garton R, Averett W, et al. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4:1525-1533.
55. Caca-Biljanovska NG, V'lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J. 2002;43:707-7l2.
56. Torras H, Aliaga A, Lopez-Estebaranz JL, et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat. 2004;15:98-103.
57. Gollnick HPM, Zaun HZ, Ruzicka T, et al. Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate: results of the first randomized double-blind multicenter half-year follow-up study. Eur J Dermatol. 1993;3:442-446.
58. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial. N Eng J Med. 1991;324:277-284.
59. Reitamo S, Spuls P, Sassolas B, et al, for the Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (Rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001;145:438-445.
60. Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54:147-156.
61. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
62. Leonardi CL, Powers JL, Matheson RT, et al, for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
63. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001;357:1842-1847.
64. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003;139:426-442.
65. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989;121:107-112.
66. Trexall [package insert]. Pomona, NY: Barr Laboratories, Inc; 2002.